Figure 2

Viability of U87MG (% of control) after incubation with EEP and temozolomide. Control – (1), Temozolomide (2 - TMZ 20 μM), EEP (3 - 10 μg/ml, 5 - 20 μg/ml, 7 - 30 μg/ml, 9 - 50 μg/ml, 11 - 100 μg/ml), EEP administered together with temozolomide (4 – EEP 10 μg/ml + TMZ 20 μM, 6 - EEP 20 μg/ml + TMZ 20 μM, 8 - EEP 30 μg/ml + TMZ 20 μM, 10 - EEP 50 μg/ml + TMZ 20 μM, 12 - EEP 100 μg/ml + TMZ 20 μM). Viability of U87MG cells after 24 (A), 48 (B) and 72 (C) hours of incubation. The results are presented as a percentage of control. A/^#p < 0.05, ^##p < 0.01, ^###p < 0.001, vs. control; * p < 0.05, *** p < 0.001, vs. TMZ; ^▲ p < 0.05, ^{▲ ▲} p < 0.01, ^{▲ ▲ ▲} p < 0.001, vs. EEP; B/ ^###p < 0.001, vs. control; * p < 0.05; ** p < 0.01; *** p < 0.001, vs. TMZ; ^{▲ ▲} p < 0.01, vs. EEP; C/^###p < 0.001, vs. control; * p < 0.05, *** p < 0.001, vs. TMZ; ^▲ p < 0.05, ^{▲ ▲ ▲} p < 0.001, vs. EEP. All statistical analysis were performed using Student-t test.